The relationship between thermogenic and potentially atherogenic effects of cigarette smoking (CS) and its cessation was investigated. Heavy smokers (n = 7, serum cotinine > 200 ng/ml, > 20 cigarettes/d) were maintained on isoenergetic, constant diets for 2 wk, 1 wk with and 1 wk without CS. Stable isotope infusions with indirect calorimetry were performed on day 7 of each phase, after an overnight fast. CS after overnight abstention increased resting energy expenditure by 5% (not significant vs. non-CS phase; P = 0.18). CS increased the flux of FFA by 77%, flux of glycerol by 82%, and serum FFA concentrations by 73% (P < 0.02 for each), but did not significantly affect fat oxidation. Hepatic reesterification of FFA increased more than threefold (P < 0.03) and adipocyte recycling increased nonsignificantly (P = 0.10). CS-induced lipid substrate cycles represented only 15% (estimated 11 kcal/d) of observed changes in energy expenditure. De novo hepatic lipogenesis was low (< 1-2 g/d) and unaffected by either acute CS or its chronic cessation. Hepatic glucose production was not affected by CS, despite increased serum glycerol and FFA fluxes. Cessation of CS caused no rebound effects on basal metabolic fluxes. In conclusion, a metabolic mechanism for the atherogenic effects of CS on serum lipids (increased hepatic reesterification of FFA) has been documented. 
Introduction
Cigarette smoking (CS)' is associated with reduced body weight and cessation of CS results in weight gain (1 -11) . The public is aware of this effect of CS, and concern about weight gain is one of the most common reasons given for continuing or returning to CS (1 -4) . Concern about weight gain after quitting smoking and the use ofCS to control body weight is particularly prevalent in women smokers (3) , who represent the fastest growing population of new smokers. Although the adverse health effects of CS greatly outweigh the benefits of lower body weight (10, 12), cosmetic or other factors clearly come into play.
The mechanism by which CS reduces body weight remains uncertain. Contrary to the general belief that CS reduces food intake, most published studies have reported increased food intake in smokers, in the range of 350 kcal/d (13, 14) , although others have reported reduced food intake in smokers (15) (16) (17) . In experimental animals, chronic administration of nicotine or exposure to CS increases oxygen consumption and results in weight loss (10) and rats given nicotine lose weight without significant reduction in food intake (18) . Recent metabolic ward studies confirm that CS has an acute calorigenic effect in humans. Smoking increases 24-h energy expenditure (EE) by 200 kcal/d (19) and intranasal or intravenous nicotine increases resting EE (REE) by 5-10% (20, 21) , although we (22) have recently observed a lower CS-induced increase in REE in heavy smokers compared with light smokers.
The metabolic basis of CS-induced calorigenesis is not understood. Nicotine causes activation of the sympathetic nervous system and the release of catechols (23, 24) , which increase EE in humans (25, 26) . CS or catechol administration increases serum FFA concentrations (27) (28) (29) . One hypothesis has been that lipolysis or elevations in serum FFA concentrations contribute to the thermogenesis of CS (26) . Consistent with this suggestion, norepinephrine-induced thermogenesis has been reported to be partially prevented by niacin (25) , a lipolysis inhibitor, in humans. A precedent exists for lipolysis/ reesterification substrate cycling contributing to thermogenesis in a hyper-adrenergic clinical condition, body burns (30) . FFA themselves are also known to increase cardiac oxygen consumption (31) .
Potentially linked but undesirable consequences of nicotine-induced lipolysis are the increased triglyceride and LDL cholesterol concentrations and reduced HDL cholesterol concentrations associated with CS (32, 33) . There is a dose-response relationship between the number of cigarettes smoked per day and serum cholesterol concentrations (34) , and cessation of CS increases HDL cholesterol (33) . In several dyslipi-demic conditions, including diabetes (35) (36) (37) , increased delivery of FFA to the liver and hepatic reesterification has been proposed to be the cause of increased VLDL triglyceride secretion and secondary alterations in serum lipids. Conversely, the mechanism by which niacin improves lipids in humans is believed to be through inhibition of lipolysis (38) (39) (40) . Hepatic reesterification of FFA may therefore link the thermogenic and atherogenic effects of CS. The effects of CS on lipolysis, serum FFA flux, and hepatic reesterification of FFA have not been determined in humans, however, nor have their relationships to CS-induced calorigenesis been evaluated. With regard to cessation of CS, the suggestion has been made (41, 42) that rebound metabolic effects occur after smoking cessation that specifically favor the deposition of body fat and could therefore provide a metabolic driving force for increased adiposity (obesity) after smoking cessation. This proposal has not been tested from a quantitative perspective, however, by measuring fat synthesis and fat oxidation under conditions of constant dietary fat and energy intake.
Our objectives in this study were to evaluate relationships between lipolytic, calorigenic, and dyslipidemic effects of CS and determine the metabolic effects of cessation of CS. Four questions were addressed. (a) What are the effects of CS on lipid metabolism, carbohydrate metabolism, and REE in heavy smokers? (b) Do substrate cycles account for the calorigenic effect of CS? (c) If potentially atherogenic effects of CS are documented, are these mechanistically linked to calorigenesis? (d) Does cessation of CS induce a rebound metabolic milieu that specifically favors accumulation of body fat (i.e., reduced fat mobilization or oxidation, increased fat synthesis) in the absence of altered food intake?
Methods
Human subjects. Volunteers were recruited by advertisement. Subjects gave written informed consent before enrollment and all protocols received prior approval from the University ofCalifornia, San Francisco, Committee on Human Research. Seven heavy smokers (serum cotinine > 200 ng/ml, > 20 cigarettes/d) were enrolled. Exclusion criteria were a history of medical illnesses (liver, kidney, metabolic, hematologic, pulmonary, gastrointestinal, neurologic), abnormalities on screening physical exam or by laboratory testing (chemistry profile, complete blood count), > 120% ideal body weight, or change in body weight > 10 lb over the preceding 6 mo. Subjects were documented to be human immunodeficiency virus seronegative (since abnormalities of lipid metabolism may be present in asymptomatic seropositivity; reference 43). Subjects using medications with potential metabolic effects (e.g., fl-blockers, f,-agonists, theophylline, diuretics, glucocorticoids, phenytoin) were also excluded. The seven subjects' age was 40±4 yr, weight was 71.3±4.7 kg, height was 172.3±3.1 cm, and body mass index was 24.0±1.3 kg/im2 (mean±SE). Duration of CS was 14±3 yr.
Study design. Subjects took part in a 2-wk inpatient metabolic ward study, 1 wk with CS and 1 wk without CS, in the General Clinical Research Center (GCRC) of San Francisco General Hospital. The sequence of CS and non-CS was randomized. Four subjects ended up in the CS phase first while three subjects were in the non-CS phase first. No effect of randomization sequence was observed here or previously (44) . Subjects were placed on a constant, weight-maintaining metabolic diet throughout the GCRC admission, to avoid potential confounding effects of cessation of CS on food intake. Diets were prepared by the metabolic kitchen, after subjects and dieticians established a daily diet providing estimated energy needs (based on Harris-Benedict equations with comparison to 3-d dietary recalls for usual intake). Compliance during the nonsmoking phase was established by measurement of breath carbon monoxide at random times throughout the day and urinary cotinine from 24-h urine collections, as described previously (45) . All subjects complained of nervousness, reduced concentration, and/or some irritability during the non-CS phase. No specific treatment for these or other withdrawal symptoms was instituted. Withdrawal scores were not measured, but we have found in previous studies that withdrawal scores are not high in a closed metabolic ward setting, due to the lack of external cues for smoking (Benowitz, N., unpublished observations).
Clinical laboratory measurements. Serum nicotine and cotinine concentrations were measured by gas chromatography (GC)/mass spectrometry (MS) (45) . Serum lipids and thyroid function tests (triiodothyronine [T3], tetraiodothyronine [T4]) were measured by standard methods (Roche Laboratories, San Francisco, CA). Serum insulin was determined by radioimmunoassay. Serum FFA concentrations were measured by GC/flame ionization detection. Quantification was by comparison to known standards, with an internal standard ofpentadecanoic acid added to the extraction mixture to determine recovery. Infusate glycerol concentrations were measured by glycerokinase enzyme assay, infusate glucose concentrations by glucose oxidase assay, and infusate palmitate concentrations by GC after extraction of the infusate with heptane/isopropyl alcohol (30:70). Urinary nitrogen was measured from 24-h collections by the Kjeldahl method.
Mass spectrometry. GC/MS (5971; Hewlett-Packard, Palo Alto, CA) was used for analysis of isotopic enrichments of serum glucose, glycerol, and fatty acid-methyl esters (FAME) from VLDL. A GC/MS (5970; HP) was used for analysis of FAME from serum. Statistical analyses. We performed two-factor repeated measures analysis of variance, with the two trial factors being smoking phase (chronic smoking vs. chronic nonsmoking) and time (baseline vs. 3-h values, the latter after acute smoking or nonsmoking). The existence of a significant chronic phase by time interaction represents statistical significance of acute smoking. If a significant interaction was found, follow-up comparisons of the four individual cell means were by Tukey's studentized range test at a procedurewise error rate of 5%.
Calculations. The rate of appearance of glycerol (Ra glycerol), RaFFA, and Ra glucose were calculated by the dilution technique (46): Ra (Amol/kg per min) = [isotope infusion rate (,gmol/kg per min)/ metabolite enrichment (M.E.)]-I, (1) where M.E. is molar excess, and I is isotype infusion rate.
Reesterification of FFA, or lipolytic substrate cycling, was calculated using the method ofWolfe et al. and Klein et al. (30, 47) . Reesterification ofFFA can be intracellular in the adipocyte, or extracellular in the liver (Fig. 1) . Reesterification in the adipocyte is calculated as the difference between 3X Ra glycerol and RaFFA, based on the assumption that glycerol released from triglycerides must escape the adipocyte, due to the absence of glycerokinase (47) 
Hepatic or extracellular reesterification is calculated as the difference between RaFFA and total body fat oxidation, representing nonoxidative FFA disposal. This calculation is based on the assumption that all FFA entering the circulation undergoes disposal by oxidation in tissues or reesterification in the liver and that fat oxidized in tissues at steady-state is derived from circulating FFA (30, 47) :
Hepatic reesterification (Amol/kg per min) = RaFFA (,umol/kg per min) -fat oxidation (Amol/kg per min). 
(6)
This technique is based on several assumptions (53), including the assumption that fat oxidized in tissues derives from circulating FFA under steady-state fasting conditions. To the extent that tissues oxidize endogenous fat stores, which did not traverse the circulation, this technique may underestimate absolute DNL. The quantitative effect of deviations from this or other assumptions ofthe method can be calculated (53), and under the metabolic conditions present in these subjects, a relatively minor influence would be exerted even if a very large error due to oxidation of endogenous fat stores were introduced (see below).
The energy cost of lipolysis/reesterification substrate cycling was calculated as described elsewhere (30) , assuming the ATP cost of triglyceride reesterification to be 8 mol ATP/mol triglyceride, and the energy value of ATP to be 20 kcal/mol ATP (54). The energy cost of DNL/fat oxidation cycling was calculated on the assumption that 28% of the energy content of carbohydrate is lost if it is converted to lipid before oxidation (54), or 3.2 kcal lost/g palmitate synthesized from glucose before oxidation.
Results
Serum nicotine, cotinine, and insulin concentrations. Basal serum nicotine concentrations after overnight abstention from CS during the smoking phase were 4.4±1.6 ng/ml (mean±SE). Blood values during the CS period were drawn immediately before starting a cigarette (representing nadir concentrations) and rose to 33.2±4.8 ng/ml after 3 h of CS (P < 0.001), remaining increased (26.7±0.8 ng/ml; P <0.001 vs. basal values) 2 h after lunch. During the non-CS week, basal levels were undetectable (< 1.0 ng/ml). Basal serum cotinine concentrations in the smoking phase were 309±40 ng/ml and were not changed significantly by acute CS (354±34 ng/ml after 3 h of CS and 347±53 ng/ml 2 h after lunch). Serum cotinine was < 10 ng/ml during the non-CS phase. Fasting serum insulin concentrations were not different between phases (6.2±0.5 ,uU/ml in CS phase and 6.9±0.7 AU/ml in non-CS phase).
(4)
Fractional DNL was calculated using mass isotopomer distribution analysis, as described previously (48-50). The ratio of excess M2/excess Ml in FAME isotopomers from VLDL reveals the true precursor (acetyl-CoA) isotopic enrichment for de novo hepatic lipogenesis (DNL) during infusion of [1-'3Clacetate, using probability analysis based on the binomial expansion (48, 51). The contribution from DNL to VLDL-palmitate is then calculated using the precursor-product relationship (48, 51 ):
where EM, is the enrichment of the Ml isotopomer of VLDL-palmitate, and A, * is the calculated asymptotic enrichment of the M, isotopomer if 100% of VLDL-palmitate were derived from hepatic DNL.
Absolute hepatic DNL was calculated by combining the calculations of fractional DNL with absolute hepatic reesterification of FFA (52) . The fraction of VLDL-palmitate derived from DNL is known (eq. 5), so that the proportion from non-DNL (reesterification) is also known (unity minus fractional DNL). By combining this with the measured apparent hepatic reesterification rate, unidirectional or absolute hepatic DNL can be calculated whether NPRQ is < 1.0 or > 1.0 (53). When NPRQ is < 1.0, the equation is: Energy expenditure. EE was measured hourly, during the 40-60th min of each hour. REE was not significantly different after an overnight fast in the CS and non-CS phases (64.4±3.5 and 64.1±4.3 kcal/h, respectively; Fig. 2 ). REE increased by 4.6% after acute CS (64.4±3.5 to 67.3±3.9 kcal/h) with increases observed in seven of seven subjects, but the change did not reach statistical significance when compared by repeated measures two-factor ANOVA to the analogous 3-h period of the non-CS phase (P = 0.18 for phase by time interaction). Ingestion ofa mixed meal increased EE by 20.3% (to 77.6±6.4 kcal/h ) in non-CS phase and by 18.9% (to 80.6±5.4 kcal/h ) in the CS phase (P = 0.82 for phase by time interaction, P < 0.01 for smoking phase vs. non-smoking phase all time points, and P < 0.002 for postprandial vs. preprandial in each phase).
Serum FFA and lipid concentrations and lipolysis. FFA concentrations did not differ in the basal state between phases, but serum FFA concentrations increased from 381±94 to 658±117 ,M after acute CS (a 73% increase, P < 0.02; Fig. 3 ).
Serum FFA concentrations were unchanged (228±36 to 281±50,uM; NS) in the non-CS phase. RaFFA was not different after an overnight fast (basal state) in the CS and non-CS phases (Fig. 4) between CS and non-CS phases in the basal state (Fig. 5) of FFA increased by 3.1 kcal/24 h (from 2.7 to 5.8 kcal/24 h) after acute CS and decreased by 2.7 kcal/24 h in the non-CS phase. For hepatic cycling, the energy cost increased from 3.2 to 11.1 kcal/d (+7.9 kcal/d) during the CS phase but did not increase from basal to 3-h measurements in the non-CS phase (from 4.1 to 2.9 kcal/d).
DNL and DNL/fat oxidation substrate cycling. Fractional DNL was low and was unchanged by acute or chronic CS (Fig.  8) . Absolute DNL was estimated to be 0.5±0.2 and 0.4±0.2 g/d at basal and 3-h time points in the non-CS phase and 0.4±0.2 g/d in the basal state for CS phase, using the recently described method (53) that combines fractional DNL with hepatic reesterification of FFA. This technique underestimates absolute DNL to the extent that hepatic reesterification ofFFA is underestimated. Since the latter depends on the assumption that intracellular fat oxidized had traversed the circulation in the form of FFA, oxidation ofintracellular fat stores will result in an underestimation of absolute hepatic DNL (53). If we allow that intracellular fat provided 25% of total fat oxidation (0.4-0.8 ,umol/kg per min), absolute hepatic DNL increases by 0.4 g/d. Even if we allow that intracellular fat provided as much substrate for oxidation as plasma FFA, absolute DNL only increases to 1.6-1.8 g/d. Thus, the low estimate of absolute hepatic DNL is not quantitatively sensitive to this deviation from the model under the metabolic conditions present here. Ra glucose. Under fasting conditions, Ra glucose is equal to hepatic glucose production. Ra glucose values were higher after 3 h than 6 h of tracer infusion in both CS and non-CS phases (Fig. 9 ). This may represent the absence of an isotopic plateau after 3 h of tracer infusion. Alternatively, hepatic glucose production may have fallen during the additional 3 h of fasting. There was no effect ofacute smoking on 6-h Ra glucose values (2.08±0.21 mg/kg per min in CS phase vs. 1.67±0.13 mg/kg per min in non-CS phase; P = 0.28).
Fuel selection. Nonprotein respiratory quotient (NPRQ) decreased from 0.88±0.02 to 0.85±0.02 during the 3-h additional fasting period in the non-CS phase, and decreased from 0.83±0.02 to 0.79±0.02 in the CS phase (significant time effect in both phases; P < 0.001). There was no significant effect of acute smoking (P = 0.73 for phase by time interaction), although the NPRQ for all smoking phase time points was significantly lower than in the nonsmoking phase (P < 0.02). After lunch, NPRQ rose to 0.85±0.03 and 0.85±0.01 for CS and non-CS phases, respectively.
Whole body fat oxidation was significantly higher in the smoking phase than the nonsmoking phase ( duced by CS that could explain increased EE? (c) Are potentially atherogenic metabolic alterations induced by CS and, if so, are they integrally related to the thermogenic effects? And, (d) are there rebound metabolic effects after cessation of CS that would specifically predispose to body fat accumulation in the absence of increased dietary energy intake?
We observed effects of acute CS on lipolysis, FFA substrate cycling, and REE but no effect on DNL, fat synthesis/fat oxidation substrate cycling, or hepatic glucose production. The lack of an effect on hepatic glucose production is interesting in view ofthe increased glycerol flux (a precursor for hepatic gluconeogenesis), increased FFA flux (a potential inhibitor of pyruvate oxidation and stimulator of gluconeogenesis, in accordance with the Randle cycle [ 55, 56] ), and increased catechol release (23,29,57) induced by CS. Compensatory hepatic autoregulatory adjustments, such as reduced glycogenolysis (58) or slight increases in serum insulin, might have restrained hepatic glucose production in these normal subjects. Although CS-induced increases in circulating FFA concentrations had been demonstrated previously (28, 29) , direct kinetic evidence that this is explicable by increased FFA entry rather than reduced FFA clearance in humans had not to our knowledge previously been reported. FFA concentrations increased proportionately to RaFFA (73 and 77%, respectively), suggesting that the primary mechanism for elevated FFA concentrations is increased production. Since catechols increase FFA concentrations in humans (25) (26) (27) and nicotine releases catechols from the sympathetic nervous system (23, 58), mobilization of FFA is presumably mediated by catechols. The effect is not persistent, though, in that basal RaFFA, Ra glycerol, and FFA concentrations were not different during the CS and non-CS phases. The lack of a lipolytic stimulatory effect after overnight abstention from CS is also consistent with the pharmacology of nicotine (54) . In contrast, the half-lives ofserum lipoproteins are much longer (several days for LDL and HDL), so that effects induced by habitual CS during the course of the day might ultimately affect fasting lipoprotein concentrations (32, 33) . Our 1-wk CS and non-CS periods were not long enough to allow differences in fasting serum lipoproteins to become apparent, however. Alteration in lipolysis/reesterification substrate cycling were observed as a consequence of acute CS. Two types of substrate cycling can be distinguished, intracellular (adipocyte) reesterification and extracellular (hepatic) reesterification (30, 47) . Measurement of Ra glycerol represents absolute lipolysis, since the adipocyte lacks glycerokinase needed to reuse glycerol released from triglyceride (47) , whereas RaFFA reflects FFA that escaped reuse within the adipocyte (Fig. 1) . The difference between 3x Ra glycerol and RaFFA therefore is an index ofintracellular reesterification ofFFA. We observed a nonsignificant (P = 0.10) increase in intracellular reesterification during acute CS (Fig. 6) . Intracellular cycling represents a thermogenic process that is relatively benign in terms of systemic metabolism, the only systemic consequence being release of glycerol. In contrast, extracellular recycling also involves entry ofFFA into the systemic circulation and reesterification in the liver, which will tend to increase hepatic VLDL-triglyceride (TG) production and secondarily alter plasma lipoproteins (35) (36) (37) (38) (39) (40) (41) .
Ofthe two possible sites for reesterification ofFFA, the liver is clearly the least desirable metabolically. Unfortunately, this process is significantly stimulated by acute CS (Fig. 7) . To the extent that CS-induced thermogenesis is mediated by substrate cycling of FFA, the sought-after thermogenic effect and the undesirable, possibly atherogenic effect on lipids might be two sides of the same coin, i.e., inseparable because they are based on a shared lipolytic mechanism. Our quantitative calculations do not support this notion, however. The total thermogenic contribution from reesterification ofFFA was calculated to be only 1 1.0 kcal/d, or 15% of observed changes in REE after acute CS in these heavy smokers. The implication is that inhibition of lipolysis and subsequent reesterification might substantially reduce dyslipidemic effects but not prevent any thermogenic effects ofCS, ifthese results in heavy smokers also apply in light smokers, in whom CS-induced thermogenesis is greater (19) (20) (21) (22) . This mechanistic question is not just of theoretical interest. Although it certainly would not be desirable from a general health point of view to administer a lipolysis inhibitor in order to allow people to continue smoking with less atherogenic risk, the question may have practical relevance for use ofnicotine patches. Niacin is believed to increase adipocyte reesterification of FFA and thereby reduce FFA release (38) . Ifthis mechanism ofaction ofniacin can be confirmed, it might in principle maintain the net reesterification rate induced by nicotine but redirect it to the adipocyte and away from the liver. We are in the process of determining the effect of nicotine patch therapy on EE and lipid metabolism.
The thermogenic effect of acute CS in these heavy smokers ( 5% and not statistically significant) was less than that reported by some previous investigators. Hofstetter et al. ( 19) reported an 8% increase in 24-h expenditure. Glauser et al. (33) found that cessation of CS caused an 8% decrease in EE. On the other hand, Perkins et al. (20) reported that intranasal nicotine (15 ,.tg/kg), which achieves serum nicotine concentrations similar to those observed in our subjects during CS, increased EE by -6%. We have elsewhere observed (22) that intravenous nicotine administration has a lower thermogenic effect in heavy smokers than light smokers, which may explain some of the differences between studies. Nevertheless, heavy smokers continue to be exposed to 
